Treatment progress of multiple myeloma / 白血病·淋巴瘤

ABSTRACT

The treatment of multiple myeloma (MM) has entered the new drug era. At the 2018 American Society of Hematology Annual Meeting, the efficacy of D-VMP and D-Rd regimens for transplant-ineligible newly diagnosed MM, DARA-VRd and IRd-Dara regimens for newly diagnosed transplant-eligible MM, and the second-generation proteasome inhibitors for relapsed and refractory MM were reported. The treatment progress of MM is reviewed in this paper.